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Background/Aims: Long-term use of aspirin can be a risk factor of peptic ulcer diseases. The aim of this study was to evaluate the 
efficacy of Albis (Daewoong Pharmaceutical Co., Ltd.) for the prevention of gastric mucosal injury caused by aspirin. 
Methods: Aspirin users were enrolled and randomized into the Albis or placebo group. Screening and follow-up endoscopy were 
performed for modified Lanza scores (MLSs). Primary outcome was measured by the incidence rate of peptic ulcer, and secondary 
outcomes were measured by the incidence rate of gastritis, improvement in MLS and subjective symptoms. 
Results: In total, 81 aspirin users were randomized, 43 in the Albis group and 38 in the placebo group. There was no incidence of peptic 
ulcer in both groups. The incidence of gastritis was significantly higher in the placebo group (44.4% vs. 10.0%, p=0.003); however, the 
scores of mucosal edema, hyperemia and hemorrhage were not statistically different between the two groups (p>0.05). The frequency 
of subjective symptoms were more improved in the Albis group than in the placebo group (p=0.023). 
Conclusions: The incidence of gastritis was lower in the group that received low-dose aspirin and Albis. The development of peptic ulcer 
due to long-term use of aspirin might be prevented with concomitant use of Albis. Clin Endosc  2017;50:179-184
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INTRODUCTION
Low-dose acetylsalicylic acid (ASA; aspirin) has been wide-
ly used for the prevention of cardio- and cerebrovascular 
diseases in patients at high risk.1,2 It is well-known that the 
risk of upper gastrointestinal (GI) tract complications such as 
ulcer, bleeding, perforation, or stricture can increase even in 
patients on low-dose ASA rather than the conventional dose.3 
Proton pump inhibitors (PPIs) are usually recommended for 
the prevention of GI complications caused by low-dose ASA. 
However, long-term maintenance with PPIs may also give rise 
other problems such as treatment cost, compliance, and ad-
verse events such as infection, osteoporosis or interaction with 
clopidogrel.4-6
Albis (Daewoong Pharmaceutical Co. Ltd., Seoul, Korea) 
contains 150 mg ranitidine, 300 mg sucralfate, and 100 mg 
bismuth subcitrate. Albis has a gastroprotective effect by 
inhibition of gastric acid secretion of histamine-2 receptor 
antagonist (H2RA), mucosa-coating and production of pros-
taglandin, respectively. It has been demonstrated that H2RAs 
prevent peptic ulcer in patients taking low-dose ASA, and 
concomitant administration of sucralfate and bismuth is 
well-tolerated and beneficial for the improvement of symp-
toms.7-9 The effect of peptic ulcer prevention in ASA-users by 
PPIs, H2RAs, and other mucoprotective agents has been eval-
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uated in many studies. However, it has not yet been demon-
strated whether the compounds of H2RA, sucralfate and 
bismuth could be effective for ulcer prevention during long-
term use of ASA.7,10,11 The aim of this study was to evaluate the 
effect of peptic ulcer prevention by Albis in patients on long-
term low-dose ASA. 
MATERIALS AND METHODS 
Patients
Patients aged between 20 to 80 years were eligible for en-
rollment if they were expected to start taking low-dose ASA 
(100 mg a day), had a modified Lanza score (MLS) of 0 or 1 
in screening endoscopy, and had no GI symptoms (Table 1).12 
The exclusion criteria were as follows: (1) presence of peptic 
ulcer or reflux esophagitis; (2) history of gastrectomy or vag-
otomy; (3) current ASA user; (4) use of PPI, H2RA, anti-plate-
lets, anti-coagulants, or nonsteroidal anti-inflammatory drugs 
within 2 weeks of enrollment; (5) comorbidity with serious 
liver disease, renal disease, or cardiac disease; (6) pregnancy or 
lactating during the study period. The study was conducted in 
accordance with the Declaration of Helsinki and approved by 
the Institutional Review Board of Seoul National University 
Hospital (IRB No. 1105-100-363). All subjects were provided 
with written informed consent before enrollment.
Study design
Enrolled patients were randomly allocated to Albis (2 tabs 
twice a day) or placebo group, and provided with the study 
medication and 100 mg of ASA a day for 12 weeks. Medi-
cations that could affect mucosal healing, such as PPIs, acid 
pump antagonists, H2RAs, and mucoprotective agents were 
prohibited during the study period. If a patient had GI symp-
toms during the study period, a rescue medication (antacid) 
was allowed up to three times a day at a standard dose. 
Primary and secondary outcomes
The primary outcome was measured by the incidence rate 
of peptic ulcer at 12 weeks of study. Peptic ulcer was defined 
as a defect more than submucosal layer in the stomach or 
duodenum with at least 3 mm in diameter measured by fol-
low-up endoscopy. 
The secondary outcomes were measured by the incidence 
rate of gastritis, improvement of MLS, subjective symptoms, 
and use of rescue medications. The presence of gastritis was 
defined as a score of 2 to 4 in MLS. The presence of mucosal 
edema, hyperemia, and hemorrhage was compared between 
the two groups. The improvement of MLS was compared in 
terms of the mean between the groups. The presence of sub-
jective symptoms was also compared in terms of frequency 
and severity of the symptoms between the groups. The use of 
rescue medication was compared between the groups.
Adverse events were also assessed during study period.
Statistical analysis
Efficacy was analyzed for the full analysis set (FAS), which 
included all randomized patients who received at least a study 
medication, with the exception of patients who did not meet 
the inclusion criteria. 
The Kaplan-Meyer method was used for determining the 
primary outcome, and the log-rank test for the statistical dif-
ferences. Fisher exact test, Student t-test, chi-square test, and 
Wilcoxon rank-sum test were used to assess the differences 
after treatment. 
The sample size was calculated based on the results of a 
previous study, and this resulted in a total of 80 subjects (40 
in each group) with an alpha error of 0.05, 80% power, and 
a dropout rate of 20%.13 All statistical tests were performed 
2-sided, and p-values less than 0.05 were considered to be 
significantly different. The data were analyzed using SPSS ver-
sion 21.0 (IBM Co., Armonk, NY, USA). 
Table 1. Modified Lanza Score and Subjective Symptoms
Grade of modified of lanza score
0 No visible lesion
1 Mucosal hemorrhage only
2 One or two erosions
3 Numerous (3–10) areas of erosions
4 Large numerous (>10) of erosions
5 Ulcer
Edema
1 None
2 Prominent 
Hyperemia
1 None
2 Mild
3 Moderate
4 Severe
Hemorrhage
1 None
2 Single lesion
3 2–5 Lesions
4 6–10 Lesions
5 >10 Lesions
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RESULTS
Patients characteristics
A total of 81 patients were randomized to either Albis (43 
patients) or placebo group (38 patients). One patient in the 
placebo group refused to receive the medication and was ex-
cluded from the study. Overall, 13 patients in the Albis group 
and 10 patients in the placebo group were excluded because 
of violation of exclusion criteria or they dropped out of the 
study. The FAS population comprised 30 patients in the Albis 
group and 27 patients in the placebo group (Fig. 1). 
The mean age was 60.3 in the Albis and 56.7 years in the 
placebo group. The proportion of males was about 50% in 
both groups. The score of MLS was 0 for over 92% of patients 
in both groups, and the score of mucosal edema, hyperemia, 
and hemorrhage were 1 in over 83% of patients in both 
groups. The baseline characteristics were not significantly 
different between the two groups in terms of sex, age, MLS, 
hyperemia, edema, and hemorrhage of mucosa (Table 2). 
Changes in gastric mucosal lesions
During the 12-week study period, no peptic ulcer developed 
in any patient. The incidence of gastritis, determined by MLS 
greater than 1, was significantly higher in the placebo group 
(44.4% vs. 10.0%, p=0.003) (Fig. 2). The mean change of MLS 
was also significantly higher in the placebo group (p=0.001). 
However, the mean changes of scores of edema, hyperemia, 
and hemorrhage of mucosa were not significantly different 
between the two groups (p>0.05) (Table 3). 
Changes in subjective symptoms and adverse events
The mean changes in the frequency and severity of subjec-
tive symptoms were 0.07 in the Albis group and 0.67 in the 
placebo group, and the values were not significantly different 
between the two groups (p>0.05) (Table 4). The mean use of 
antacids as a rescue medication was 18.2 in the Albis group 
and 17.6 in the placebo group, and the values were not sig-
nificantly different between the two groups (p=0.92). The in-
cidence of drug-related adverse events was 37.2% in the Albis 
group and 18.9% in the placebo group, and the value was not 
also significantly different between the two groups (p=0.09). 
The most common adverse events were GI discomforts such 
81 Assessd for eligibility and 
randomized
1 Excluded
- Declined to participate
43 Albis37 Placebo
12 Lost to follow-up
1 Study violation
30 FAS population
7 Lost to follow-up 
3 Study violation
27 FAS population
Fig. 1. Flow of the study population. A total of 81 patients were enrolled and 
randomized to Albis (Daewoong Pharmaceutical Co., Ltd.) or placebo group. 
Thirty patients in Albis group and 27 patients in placebo group were analyzed 
in full analysis set (FAS).
Table 2. Baseline Characteristics of Patients
Characteristic Albis (n=30) Placebo (n=27) p-value
Median age, yr 60.3 56.7 0.19
Male sex, % 15 (50.0) 13 (48.2) 0.89
MLS 0, % 29 (96.7) 25 (92.6) 0.60
Edema 1, % 29 (96.7) 25 (92.6) 0.60
Hyperemia 1, % 25 (83.3) 25 (92.6) 0.67
Hemorrhage 1, % 29 (96.7) 26 (96.3) 0.73
Values are presented as number (%).
MLS, modified Lanza score.
Fig. 2. The incidence of gastric mucosal injury in terms of modified Lanza 
scores. The incidence of gastric mucosal injury was higher in the placebo 
group. 
0
5
10
15
20
25
30
35
40
45
50
Placebo
Albis
Treatment group
12/27 (44.4%)
3/30 (10.0%)
p-value=0.003
Pr
op
or
tio
n 
of
 p
at
ien
ts 
(%
)
182   
as abdominal pain, constipation, and flatulence (Table 5). No 
serious adverse event was reported in both groups during the 
study period.
DISCUSSION
In this study, Albis (containing ranitidine, sucralfate, and 
bismuth) prevented the gastric mucosal injury provoked by 
long-term use of ASA. There was no development of peptic 
ulcer in either of the groups during the study period. This 
might be due to the study period being too short to allow 
peptic ulcer to develop by the use of low-dose ASA. However, 
gastric mucosal injury measured by the MLS developed, but 
was reduced by concomitant use of Albis. Although several 
studies have reported the efficacy of PPIs or H2RAs in the 
prevention of peptic ulcer and gastric mucosal injury caused 
by ASA, there is no report of the efficacy of fixed-dose com-
bination of H2RA, sucralfate, and bismuth.3,7,11,14-17 This is the 
first prospective trial to evaluate the efficacy of combination 
of H2RA, sucralfate, and bismuth for the prevention of peptic 
ulcer or gastric mucosal injury due to long-term use of low-
dose ASA.
Peptic ulcer did not develop even in placebo group during 
study period. As only ASA was administered in the group 
with low risk of peptic ulcer, the risk of peptic ulcer develop-
ment was expected to be low. Moreover, the duration of the 
study was too short for peptic ulcer to develop due to ASA 
use even in the placebo group. In a previous study similar to 
ours but conducted over 26 weeks, patients developed peptic 
ulcer.10 Therefore, the effect of Albis in preventing peptic ulcer 
caused by ASA may be better demonstrated if the study peri-
od is extended over 26 weeks.10
Protection against mucosal injury caused by ASA use was 
higher in the Albis group than in the placebo group, and the 
changes in MLS scores were lower in the Albis group than in 
the placebo group. However, mucosal injury due to ASA did 
not aggravate any subjective symptoms, which were minimal 
Table 3. Changes of MLS and Secondary Outcomes between the Two Groups
Variable Albis (n=30) Placebo (n=27) p-value
Change of MLS 0.17±0.65 1.19±1.39 0.001
Changes of edema score 0.00±0.26 0.00±0.28 1.000
Changes of hyperemia score –0.03±0.41 0.04±0.19 0.426
Changes of hemorrhage score 0.03±0.56 0.11±0.42 0.625
Values are presented as mean±SD.
MLS, modified Lanza score.
Table 4. The Mean Changes of Frequency and Severity of Subjective Symptoms
Variable Albis (n=30) Placebo (n=27) p-value
Change of subjective symptoms score 0.07±2.83 0.67±1.66 0.321
Values are presented as mean±SD.
Table 5. Adverse Events between the Two Groups
Variable Albis (n=43) Placebo (n=37) p-value
Patients with all adverse event 16 (37.2) 7 (18.9) 0.09
Gastrointestinal symptoms 10 (23.2) 4 (10.8)
Headache, dizziness 2 (4.7) 2 (5.4)
Nasopharyngitis 1 (2.3) 3 (8.1)
Edema 1 (2.3) 0 (0.0)
Chest discomfort 2 (4.7) 0 (0.0)
Conjunctival hemorrhage 1 (2.3) 0 (0.0)
Breast calcification 0 (0.0) 1 (2.7)
Phlebitis 1 (2.3) 0 (0.0)
Serious adverse event 0 (0.0) 0 (0.0) 1.00
Use of rescue medicine, mean 18.2 17.6 0.92
Values are presented as number (%).
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in both groups owing to a low dose of only ASA being admin-
istered and due to the duration of study being relatively short.
ASA inhibits the cyclooxygenase pathway in the ara-
chidonic acid metabolism. This results in inhibition of the 
production of prostaglandin and thromboxane which are 
indispensable for gastric mucoprotection and platelet aggrega-
tion. H2RAs inhibit the secretion of gastric acid and thereby 
protect the gastric mucosa from injury provoked by a de-
creased production of prostaglandin and thromboxane caused 
by ASA. Sucralfate exerts gastroprotective effects by coating 
and binding to mucosal injury caused by ASA. Bismuth also 
protects against mucosal injury caused by ASA by increasing 
the secretion of prostaglandin. Therefore, Albis can protect 
against gastric mucosal injury caused by ASA, via various 
mechanisms of H2RA, sucralfate, and bismuth.
Helicobacter pylori infection induces chronic inflammation 
of the gastric mucosa, which can be aggravated by long-term 
use of ASA. ASA can be a risk factor for peptic ulcer in H. 
pylori-positive patients.18 However, H. pylori eradication alone 
increases the risk of peptic ulcer more than H. pylori eradica-
tion combined with PPI maintenance in long-term ASA users. 
Therefore, H. pylori eradication is not currently recommended 
for long-term ASA users without a previous history of peptic 
ulcer.19,20 
As the status of H. pylori infection was not evaluated in this 
study, the effect of Albis in the prevention of gastric mucosal 
injury caused by ASA could not be analyzed according to H. 
pylori infection. Although the influence of H. pylori infection 
on our results could not be evaluated, no ulcers were devel-
oped during the study period in both the treatment and place-
bo groups. Furthermore, the mucosal injury might not differ 
per the status of H. pylori infection. In previous studies, the 
preventive effect of PPIs on peptic ulcers in long-term ASA 
users was not different according to the status of H. pylori in-
fection at 12 weeks, but evident in H. pylori-negative patients 
at 26 weeks.10,14
The subjective symptoms were not significantly different 
between the treatment and placebo groups. Although muco-
sal injuries were more evident in the placebo group, they were 
not sufficient to provoke patient discomfort. The incidence of 
adverse events was also not significantly different between the 
groups.
This study had some limitations. Firstly, the drop-out rate 
was too high and the FAS population was too small to com-
pare the results between the treatment and placebo groups. 
Secondly, the study period was too short to provoke the de-
velopment of ulcer by ASA. Thirdly, the effect of H. pylori 
infection was not evaluated, which could influence the devel-
opment of ulcers in long-term ASA users. Nevertheless, this is 
the first report on the gastroprotective effect of a combination 
of ranitidine, sucralfate, and bismuth in long-term ASA users.
In conclusion, Albis prevented gastric mucosal injury in 
ASA users. However, further studies are warranted to demon-
strate the preventive effect of Albis against peptic ulcer in 
long-term ASA users for over 24 weeks. 
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